Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
521

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to the letter 'Mental illness and epilepsy are not attributable to out-of-hospital resuscitation after cardiac arrest unless other causes have been ruled out'.

European journal of emergency medicine : official journal of the European Society for Emergency Medicine·2026
Same author

HIF-1α attenuates ferroptosis-associated dermal fibroblast senescence via modulation of NF-κB-DPP4 signaling.

Journal of translational medicine·2026
Same author

Association of long-COVID with major adverse cardiovascular events and mortality: a real-world data cohort study.

BMC cardiovascular disorders·2026
Same author

TAPINTO: A Novel Algorithm for Tumor-Associated Antigen Prediction Based on Information about Target Overexpression.

Computational and structural biotechnology journal·2026
Same author

Delayed mammography screening and advanced breast cancer: variation across age and income groups.

BMC public health·2026
Same author

Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database.

Immunity, inflammation and disease·2026

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.5K

Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study.

Cheng-Hsun Chuang1,2,3, Ping-Kun Tsai3,4,5,6, Shih-Wen Kao7,8

  • 1Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan.

Oncology Research
|January 8, 2026
PubMed
Summary

Starting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) early for type 2 diabetes may reduce cancer risk. Benefits were more significant for individuals with obesity, suggesting dual metabolic and oncologic advantages.

Keywords:
Glucagon-like peptide-1 (GLP-1) receptor agonistscancer riskcohort studyobesitytype 2 diabetes mellitus

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

709
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

3.2K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.5K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

709
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

3.2K

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is a growing global health concern.
  • The potential impact of early glucose-lowering therapies on cancer risk is an area of active investigation.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for T2DM management.

Purpose of the Study:

  • To investigate if initiating GLP-1 RAs within 3 months of T2DM diagnosis affects subsequent overall and site-specific cancer risk.
  • To examine if baseline body-mass index (BMI) modifies the association between early GLP-1 RA use and cancer risk.

Main Methods:

  • Retrospective cohort study utilizing electronic health records from the TriNetX U.S. research network.
  • 1:1 propensity score matching of 183,264 adult T2DM patients (GLP-1 RA users vs. non-users).
  • Cox proportional hazards models and Kaplan-Meier analysis were used to estimate cancer risk, with stratified analysis by BMI.

Main Results:

  • Early GLP-1 RA initiation was associated with a modest but significant reduction in overall cancer risk (HR 0.93).
  • Significant risk reductions were observed for digestive (HR 0.81), respiratory (HR 0.66), and female genital (HR 0.87) cancers.
  • The cancer risk reduction was more pronounced in patients with BMI ≥ 30, especially for pancreatic and colorectal cancers.

Conclusions:

  • Early GLP-1 RA therapy in T2DM patients is linked to a modest decrease in overall cancer risk.
  • The benefits of early GLP-1 RA use on cancer risk appear more significant in individuals with obesity (BMI ≥ 30).
  • These findings suggest GLP-1 RAs possess both metabolic and potential oncologic benefits when initiated promptly in T2DM management.